Abuse potential of zomepirac

Rolley E. Johnson; Donald R. Jasinski; Theresa R. Kocher

Abuse potential of zomepirac

Rolley E. Johnson, Donald R. Jasinski, Theresa R. Kocher

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Zomepirac sodium, a nonsteroidal anti- inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800-mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused.

Original language	English (US)
Pages (from-to)	386-389
Number of pages	4
Journal	Clinical Pharmacology and Therapeutics
Volume	34
Issue number	3
State	Published - Sep 1983

ASJC Scopus subject areas

Pharmacology

Cite this

@article{fc279c5fd3634cb9984e08e2d7e21437,

title = "Abuse potential of zomepirac",

abstract = "Zomepirac sodium, a nonsteroidal anti- inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800-mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused.",

author = "Johnson, {Rolley E.} and Jasinski, {Donald R.} and Kocher, {Theresa R.}",

year = "1983",

month = sep,

language = "English (US)",

volume = "34",

pages = "386--389",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Abuse potential of zomepirac

AU - Johnson, Rolley E.

AU - Jasinski, Donald R.

AU - Kocher, Theresa R.

PY - 1983/9

Y1 - 1983/9

N2 - Zomepirac sodium, a nonsteroidal anti- inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800-mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused.

AB - Zomepirac sodium, a nonsteroidal anti- inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800-mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused.

UR - http://www.scopus.com/inward/record.url?scp=0020525855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020525855&partnerID=8YFLogxK

M3 - Article

C2 - 6883915

AN - SCOPUS:0020525855

SN - 0009-9236

VL - 34

SP - 386

EP - 389

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 3

ER -

Abuse potential of zomepirac

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this